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REPLY
We appreciate the opportunity to reply to the letter sent by Dr.
d’Udekem and colleagues concerning the article we recently
published in JACC.
Although we are grateful for their interest in our work, we
would like to address the issues they have raised. First, their
statement that “. . . all patients operated on . . . showed neither
clinical improvement nor regression of ventricular volumes after
reoperation . . . ” is incorrect. As our article clearly stated, most of
our symptomatic patients had a significant clinical improvement
postoperatively (24% NYHA class $ III preoperatively vs. 0%
postoperatively, p , 0.001) (1). Unfortunately, this could not be
confirmed objectively (the same mean duration of exercise and
external workload was achieved both pre- and postoperatively).
Furthermore, although the mean right ventricular volume and
function did not improve postoperatively, about one-third of our
patients did show such improvement as depicted in Figures 1, 2
and 3 of our article (1). Unfortunately, the relatively small number
of patients made it impossible to determine which of the many
factors analyzed favored such a response. Finally, we disagree with
the statement that “the . . . effect of this [bulky bioprosthesis] . . .
is to further increase the size of the right ventricular cavity” . . . and
impede contraction of the pulmonary infundibulum by virtue of its
extensive transannular patching. They are correct that we do
enlarge the outflow tract to accommodate as large a prosthesis as
possible, but the patch to do this is largely from the annulus
distally. Proximal to the annulus, the patch extends into the
infundibulum a distance of 10 to 15 mm. We do not believe that
a 10 to 15 mm incision below the pulmonary annulus would have
an important impact on right ventricular volume and function. We
do agree, however, that any incision in the right ventricle should be
avoided or minimized as much as possible in order to potentiate
maximal postoperative functional recovery.
The issue of pulmonary valve replacement in adults late after
repair of tetralogy of Fallot remains a controversial one and we
again thank Dr. d’Udekem and colleagues for their interest in our
work.
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A Real Smoker’s Paradox
The article by van Domburg et al. (1) in the September issue of the
Journal presented detailed but not unexpected findings with regard
to the hazards of cigarette smoking. However, I wonder whether
the authors are aware that in Figure 2 of their paper, there is a
graph which implies that the survival rate of cigarette smokers who
quit after their bypass operation is significantly better than those
who continue to smoke, but also significantly better than those
who have never smoked. One would have to conclude from this
data that the best chances of survival are among those who smoke
up until the time of their surgery and then quit, rather than never
to smoke at all. This would truly be a smoker’s paradox if in fact
it is correct!
I would appreciate some explanation from the authors.
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REPLY
We appreciate the comments of Dr. Shander regarding our recent
article in JACC (1). In his comments he concluded that “the best
chances of survival are among those who smoke up until the time
of their surgery and then quit rather than never to smoke at all.”
We have proven that patients who quit smoking after bypass
surgery are significantly better off than those who continue to
smoke. However, in our study we only compared the patients who
quit smoking with patients who continued smoking. Because of its
irrelevancy, we did not compare the patients who quit smoking
with patients who did not smoke. Furthermore, we did not use the
term “never smoked” but used the term “nonsmoking.” We did not
distinguish between patients who have never smoked and ex-
smokers (patients who had stopped smoking before the time of
surgery), and we combined these two groups into one nonsmokers’
group at the time of surgery. The smoking habits at the time of
surgery did not influence survival during the follow-up period.
This smoker’s paradox is partly explained by the difference in
baseline characteristics such as an age difference (smokers were
four years younger than nonsmokers). Another explanation could
be selection bias, as many smokers tend to die of fatal myocardial
infarctions before they have the chance to undergo coronary bypass
surgery (2).
Finally, the survival rates of the nonsmokers were probably
positively influenced by the ex-smokers. In conclusion, the worse
condition of the nonsmokers as compared with the smokers at the
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time of surgery largely explains the survival differences between
nonsmokers and patients who quit smoking.
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Ideal Weight, Body Composition and
Lipid Levels: An Unresolved Dilemma?
Osman et al. (1) have shown that in chronic heart failure (CHF),
peak VO2 corrected for lean body mass is a more powerful predictor
of clinical outcome than the traditional peak VO2 adjusted for total
body weight. We thank the authors for addressing this important
issue, since the estimation of exercise capacity is significantly
influenced by body fat content (2). There are, however, several
points we would like to comment upon. In addition to the findings
of Osman et al. (1), we found that mildly obese CHF patients had
a better prognosis (3). Although Osman et al. (1) demonstrated
that subjects reaching the set end points had significantly reduced
body fat mass, they did not provide statistical data regarding the
impact of body fat mass on prognosis. Of note, the majority of
subjects in their study had mild-to-moderate CHF and an average
body weight of 89 kg (BMI [body mass index] 28.9 kg/m2), in
keeping with metabolic stability. However, CHF is increasingly
recognized as a metabolic syndrome with both fat and muscle mass
being reduced during disease progression.
Osman et al. (1) state that fat tissue is metabolically inactive, and
this is certainly true in the setting of acute exercise testing.
Alternatively, fat mass may be an indicator of preserved metabolic
efficiency and/or energy reserve in CHF, and as such may relate to
enhanced survival. Therefore, a mild increase in BMI might not be
considered an adverse risk factor in CHF, and as such we would be
most grateful if Osman et al. (1) could comment on this based on
the data from their study. Obesity, and in particular fat mass, has
primarily been considered to relate to an unfavorable atherogenic
lipoprotein profile, recognized as one of the major risk factors
contributing to the development of ischemic heart disease (IHD).
Whereas patients with IHD are metabolically stable, patients with
CHF can develop substantial catabolism (4).
In view of this, we have hypothesized that low serum cholesterol
may be associated with impaired prognosis in CHF (5). We have
clinical data supporting this hypothesis, which has been presented
recently (6). A recent study by Horne et al. (7) demonstrated that
total cholesterol and atherogenic lipid indices were not predictors
of impaired clinical outcome in severe IHD. However, an elevated
C-reactive protein (a nonspecific marker of systemic inflammation)
and reduced left ventricular ejection fraction (reflecting the pres-
ence of CHF) were independently related to mortality. Thus, in
this study, systemic inflammation but not lipid levels appear to be
linked to increased mortality in CHF. Of note, statin therapy was
associated with marked beneficial effects on clinical outcome,
independently of lipid levels. These findings together lend support
to our hypothesis that, in CHF, higher body fat and serum
cholesterol may relate to enhanced survival, and perhaps statins
actually exert beneficial effects by mechanisms other than lipid-
lowering (5). In addition, they may also increase the turnover of
endotoxin-laden lipoproteins in the plasma by inhibiting endoge-
nous cholesterol synthesis. This might then lead to endotoxin
elimination, reduced cytokine production and, finally, less systemic
immune activation.
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We thank Drs. Schmidt and Rauchhaus for their insightful
comments and appreciate the opportunity to delineate the issue of
body fat and prognosis in chronic heart failure (CHF).
In our investigation (1), obesity (body mass index [BMI]
.30 kg/m2) was encountered in 37% of the cohort, with no
statistically significant difference in clinical outcome among the
obese and nonobese (10% of obese patients reached the end point
of death or urgent transplantation compared with 18% of the
nonobese patients, p 5 0.1). Furthermore, although percent fat
was lower in those who reached the primary end point than in
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